Anti‐CD19 and anti‐BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem‐cell transplantation for high‐risk newly diagnosed multiple myeloma-Reference-Cited by-同舟云学术

Anti‐CD19 and anti‐BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem‐cell transplantation for high‐risk newly diagnosed multiple myeloma

Published:2022-02-09 Issue:5 Volume:97 Page:537-547
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Shi Xiaolan¹^ORCID,Yan Lingzhi¹^ORCID,Shang Jingjing¹,Kang Liqing²,Yan Zhi¹,Jin Song¹,Zhu Mingqing¹,Chang Huirong¹,Gong Feiran¹,Zhou Jiazi¹,Chen Guanghua¹,Pan Jinlan¹,Liu Dandan¹,Zhu Xiaming¹,Tang Fang¹,Liu Minghong¹,Liu Wei³,Yao Feirong⁴,Yu Lei²,Wu Depei¹⁵⁶,Fu Chengcheng¹⁵⁶^ORCID

Affiliation:

1. National Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou China

2. Shanghai Unicar‐Therapy Bio‐medicine Technology Co. Ltd. Shanghai China

3. Department of Pathology The First Affiliated Hospital of Soochow University Suzhou China

4. Department of Radiology The First Affiliated Hospital of Soochow University Suzhou China

5. Institute of Blood and Marrow Transplantation Collaborative Innovation Center of Hematology, Soochow University Suzhou China

6. State Key Laboratory of Radiation Medicine and Protection Soochow University Suzhou China

Funder

Jiangsu Provincial Key Research and Development Program

National Key Research and Development Program of China

National Natural Science Foundation of China

National Science and Technology Major Project

Priority Academic Program Development of Jiangsu Higher Education Institutions

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26486

Reference53 articles.

1. Multiple myeloma

2. Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline

3. Autologous Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Therapies

4. Induction Therapy for Newly Diagnosed Multiple Myeloma

5. Risk factors in multiple myeloma: is it time for a revision?

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Updates on CAR T cell therapy in multiple myeloma;Biomarker Research;2024-09-12

2. How can we improve the successful identification of patients suitable for CAR-T cell therapy?;Expert Review of Molecular Diagnostics;2024-09-11

3. Effects of Consolidation Therapy With Autologous Hematopoietic Stem Cell Transplantation After BCMA-CAR T-Cell Therapy on the Survival of Patients With Relapsed or Refractory Multiple Myeloma;Transplantation and Cellular Therapy;2024-09

4. Chimeric antigen receptor T-cells: a review on current status and future directions for relapsed/refractory multiple myeloma;Frontiers in Oncology;2024-08-08

5. CAR T cell combination therapies to treat cancer;Cancer Cell;2024-08